DYN
Price
$11.24
Change
+$0.05 (+0.45%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
1.59B
80 days until earnings call
GERN
Price
$1.35
Change
+$0.08 (+6.25%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
816.66M
87 days until earnings call
Interact to see
Advertisement

DYN vs GERN

Header iconDYN vs GERN Comparison
Open Charts DYN vs GERNBanner chart's image
Dyne Therapeutics
Price$11.24
Change+$0.05 (+0.45%)
Volume$61.49K
Capitalization1.59B
Geron
Price$1.35
Change+$0.08 (+6.25%)
Volume$144.13K
Capitalization816.66M
DYN vs GERN Comparison Chart in %
Loading...
DYN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DYN vs. GERN commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DYN is a Hold and GERN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (DYN: $11.19 vs. GERN: $1.28)
Brand notoriety: DYN and GERN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DYN: 0% vs. GERN: 114%
Market capitalization -- DYN: $1.59B vs. GERN: $816.66M
DYN [@Biotechnology] is valued at $1.59B. GERN’s [@Biotechnology] market capitalization is $816.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DYN’s FA Score shows that 1 FA rating(s) are green whileGERN’s FA Score has 0 green FA rating(s).

  • DYN’s FA Score: 1 green, 4 red.
  • GERN’s FA Score: 0 green, 5 red.
According to our system of comparison, DYN is a better buy in the long-term than GERN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DYN’s TA Score shows that 5 TA indicator(s) are bullish while GERN’s TA Score has 4 bullish TA indicator(s).

  • DYN’s TA Score: 5 bullish, 4 bearish.
  • GERN’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, DYN is a better buy in the short-term than GERN.

Price Growth

DYN (@Biotechnology) experienced а +11.34% price change this week, while GERN (@Biotechnology) price change was +9.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.22%. For the same industry, the average monthly price growth was +31.78%, and the average quarterly price growth was +19.63%.

Reported Earning Dates

DYN is expected to report earnings on Oct 30, 2025.

GERN is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+22.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DYN($1.59B) has a higher market cap than GERN($817M). DYN YTD gains are higher at: -52.504 vs. GERN (-63.842). GERN has higher annual earnings (EBITDA): -114.49M vs. DYN (-437.37M). DYN has more cash in the bank: 684M vs. GERN (397M). DYN (121M) and GERN (122M) have identical debt. GERN has higher revenues than DYN: GERN (116M) vs DYN (0).
DYNGERNDYN / GERN
Capitalization1.59B817M194%
EBITDA-437.37M-114.49M382%
Gain YTD-52.504-63.84282%
P/E RatioN/AN/A-
Revenue0116M-
Total Cash684M397M172%
Total Debt121M122M99%
FUNDAMENTALS RATINGS
GERN: Fundamental Ratings
GERN
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
76
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DYNGERN
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
87%
Momentum
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
85%
MACD
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 4 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
82%
Advances
ODDS (%)
Bullish Trend 6 days ago
85%
Bullish Trend 11 days ago
73%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
78%
Aroon
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
DYN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FAVAX24.300.18
+0.75%
Fidelity Advisor Equity Value A
EQNVX22.880.15
+0.66%
MFS Equity Income R6
MSFJX19.750.05
+0.25%
MFS Total Return R4
AFNIX25.910.06
+0.23%
Bahl & Gaynor Income Growth I
TGPEX10.84-0.04
-0.37%
T. Rowe Price Global Impact Equity Inv

DYN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DYN has been loosely correlated with RNA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then RNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYN
1D Price
Change %
DYN100%
N/A
RNA - DYN
58%
Loosely correlated
-2.59%
CRNX - DYN
54%
Loosely correlated
-3.69%
XNCR - DYN
53%
Loosely correlated
-1.23%
SYRE - DYN
52%
Loosely correlated
N/A
IDYA - DYN
50%
Loosely correlated
+3.08%
More

GERN and

Correlation & Price change

A.I.dvisor indicates that over the last year, GERN has been loosely correlated with SER. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
-1.54%
SER - GERN
65%
Loosely correlated
+1.10%
SYRE - GERN
39%
Loosely correlated
N/A
UTHR - GERN
38%
Loosely correlated
+0.69%
DYN - GERN
35%
Loosely correlated
N/A
DNTH - GERN
35%
Loosely correlated
-2.04%
More